Adverum Biotechnologies, Inc., formerly Avalanche Biotechnologies, Inc., is a gene therapy company. The Company is engaged in discovering and developing gene therapeutics for ophthalmic diseases. It is focused on developing gene therapy programs to address unmet medical needs of diseases, such as wet age-related macular degeneration (wAMD), alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE). The Company's principal product pipeline includes ADVM-022/032 for the treatment of wAMD, and ADVM-043 and ADVM-053 for the treatment of A1AT and HAE respectively. The ADVM-22 and ADVM-032 are anti- vascular endothelial growth factor (VEGF) gene therapy candidates administered intra-viterally. ADVM-043 induces long-term A1AT protein levels with a single intravenous administration. Through the partnership programs with Editas Medicine, Inc. and Regeneron Pharmaceuticals, Inc., the Company develops gene therapies for inherited retinal and ocular diseases.